Evidence map›Paper›PMID 28499444›Full record

ArticleBMC cancer2017

A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.

Charlotte Demoor-Goldschmidt, Delphine Drui, Isabelle Doutriaux, Gérard Michel, Pascal Auquier, Agnès Dumas, Claire Berger, Valérie Bernier, Sandrine Bohrer, Pierre-Yves Bondiau and 19 more

Abstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Models of Care for Survivors of Childhood Cancer From Across the Globe: Advancing Survivorship Care in the Next Decade.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Charlotte Demoor-GoldschmidtCentre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, 94807, Villejuif, France. Charlotte.Demoor@inserm.fr.
Delphine DruiDepartment of endocrinology, CHU de Nantes, 44000, Nantes, France.
Isabelle DoutriauxDepartment of radiology, Institut de Cancérologie de l'Ouest - René Gauducheau, 44800, Saint Herblain, France.
Gérard MichelService d'hématologie et oncologie pédiatrique, Hôpital d'enfants La Timone, Marseille, France.
Pascal AuquierUnité de recherche EA 3279, Université Aix-Marseille, Marseille, France.
Agnès DumasCentre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, 94807, Villejuif, France.
Claire BergerClaire Berger, hemato-oncology pediatric department, chu nord st Etienne, cedex, 42055, St Etienne, France.
Valérie BernierDepartment of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
Sandrine BohrerOncology and Hematology Unit, CHU de Saint Denis de La Réunion, Saint Denis, France.
Pierre-Yves BondiauDepartment of Radiotherapy, Centre Antoine Lacassagne, Nice, France.
Bruno FilhonDepartment of Pediatric Hematology and Oncology, Rouen University Hospital, Rouen, France.
Brice FresneauCentre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, 94807, Villejuif, France.
Claire FreyconService d'hématologie et d'oncologie pédiatrique du CHU de Grenoble, Grenoble, France.
Dinu StefanDepartment of Radiation Oncology, Centre François Baclesse, Caen, France.
Sylvie HelfreDepartment of Radiation Oncology, institut Curie, Paris, France.
Angela JacksonCentre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, 94807, Villejuif, France.
Christine KerrDepartment of Radiation Oncology, institut du cancer de Montpellier, Montpellier, France.
Anne LaprieDepartment of Radiation Oncology, IUCT Oncopole, Toulouse, France.
Julie LeseurDepartment of Radiation Oncology, centre Eugène-Marquis, Rennes, France.
Marc-André MahéDepartment of Radiation Oncology, ICO, Nantes, France.
Caroline OudotPediatric Oncology Department, Hôpital de la Mère et de l'Enfant, 87042, Limoges, France.
Claire PluchardPediatric Oncology Department, chu Reims, hôpital américain, Reims, France.
Stéphanie ProustPediatric Oncology Department, chu Angers, Angers, France.
Hélène Sudour-BonnangePediatric Oncology Unit, Anti Cancer Center Oscar Lambret, cedex, 59020, Lille, France.
Céline VigneronDepartment of Radiation Oncology, Centre de lutte contre le Cancer Paul Strauss, Strasbourg, France.
Nathalie LassauImaging Department, Gustave Roussy Cancer Campus Grand Paris, IR4M UMR8081, Université Paris Sud, Villejuif, France.
Martin SchlumbergerDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, 94805, Villejuif, France.
Cécile Faure ConterPediatric Oncology Department, Centre Léon-Bérard, Lyon, France.
Florent de VathaireCentre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, 94807, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival of childhood, adolescent and young adult (CAYA) cancers has increased with progress in the management of the treatments and has reached more than 80% at 5 years. Nevertheless, these survivors are at great risk of second cancers and non-malignant co-morbidities in later life. DeNaCaPST is a non-interventional study whose aim is to organize a national screening for thyroid cancer and breast cancer in survivors of CAYA cancers. It will study the compliance with international recommendations, with the aim, regarding a breast screening programme, of offering for every woman living in France, at equal risk, an equal screening.

methodDeNaCaPST trial is coordinated by the INSERM 1018 unit in cooperation with the LEA (French Childhood Cancer Survivor Study for Leukaemia) study's coordinators, the long term follow up committee and the paediatric radiation committee of the SFCE (French Society of Childhood Cancers). A total of 35 centres spread across metropolitan France and la Reunion will participate. FCCSS (French Childhood Cancer Survivor Study), LEA and central registry will be interrogated to identify eligible patients. To participate, centers agreed to perform a complete "long-term follow-up consultations" according to good clinical practice and the guidelines of the SFCE (French Society of Children Cancers). DISCUSSION: As survival has greatly improved in childhood cancers, detection of therapy-related malignancies has become a priority even if new radiation techniques will lead to better protection for organs at risk. International guidelines have been put in place because of the evidence for increased lifetime risk of breast and thyroid cancer. DeNaCaPST is based on these international recommendations but it is important to recognize that they are based on expert consensus opinion and are supported by neither nonrandomized observational studies nor prospective randomized trials in this specific population. Over-diagnosis is a phenomenon inherent in any screening program and therefore such programs must be evaluated.

Indexed as

BreastBreast NeoplasmsEarly Detection of CancerFemaleFranceHumansMass ScreeningNeoplasms, Second PrimaryThyroid GlandThyroid NeoplasmsBreastBreast cancer screeningChildhood cancerChildhood cancer survivorSecondary cancerSecond cancerSurvivorThyroidThyroid cancer screening

Identifiers

PMID28499444
PMCPMC5427546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.